Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?

ABSTRACT:

Background

Stage III Non-small cell lung cancer (NSCLC) is a heterogenous disease with novel treatment options. Recently, immunotherapy has attracted a lot of attention for advanced NSCLC.

Objective

The objective of our study was to assess the efficacy and safety of neoadjuvant immuno-chemotherapy for resectable stage III NSCLC.

Methods

We analyzed 11 stage III primary NSCLC surgical cases who had undergone standard lobectomy or bronchial sleeve resection and lymph node dissection between December 2020 and July 2021. The data analyzed included basic clinical features, serum levels of key biomarkers, clinical efficacy in the perioperative period, postoperative pathological results, postoperative complications and the incidence rates of Immune-Related Adverse Events.

SUBMITTER: Yao Y 

PROVIDER: S-EPMC9018103 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature